What Cancer Metabolism Research Really Tells Us About Mitochondria, Glucose, and Cellular Health
Cancer is usually discussed in terms of genetic mutations, abnormal cell growth, and treatments designed to destroy malignant cells. Those are important parts of the picture, but cancer also involves profound changes in the way cells produce and use energy. Nearly a century ago, biochemist Otto Warburg observed that many cancer cells consume large amounts of glucose and produce lactate even when oxygen is available. His discovery opened an entirely different way of thinking about cancer, one that continues to influence research today.
Ray Peat and Georgi Dinkov have helped bring this metabolic perspective to a wider audience. Their discussions emphasize mitochondrial function, oxidative metabolism, stress hormones, inflammation, and the biochemical environment surrounding cancer cells. I find this perspective valuable because it encourages us to look beyond isolated nutrients and consider how energy metabolism affects cellular health. However, understanding cancer metabolism is different from proving that restoring normal metabolism can eliminate cancer, and that distinction matters when we're discussing something this serious.
What Warburg Actually Discovered
Under ordinary aerobic conditions, many healthy cells break down glucose through glycolysis and then use the resulting pyruvate in the mitochondria to produce additional ATP through oxidative phosphorylation. Cancer cells often behave differently, converting substantial amounts of glucose into lactate even when oxygen is available. This phenomenon is called aerobic glycolysis, or the Warburg effect, and it has become one of the most widely studied features of cancer metabolism.
Warburg believed that damaged mitochondrial respiration was the primary cause of cancer and that increased fermentation developed as a consequence. His hypothesis was enormously influential, but subsequent research has shown that the relationship is more complicated. Many tumors retain functional mitochondria, and some depend heavily on oxidative phosphorylation for survival, growth, or resistance to treatment. Cancer cells can also switch between different fuels depending on oxygen availability, nutrient supply, genetic changes, and conditions within the tumor.
One reason the Warburg effect is so important is that glycolysis supports more than ATP production. It supplies intermediates needed to manufacture nucleotides, amino acids, and lipids, all of which are required for rapidly dividing cells. Lactate also influences the surrounding tumor environment, including immune activity and communication between cells. These adaptations can provide advantages to cancer cells even when their mitochondria remain functional.
This is why the familiar claim that sugar simply feeds cancer misses so much of the underlying biology. Cancer cells use glucose, but so do healthy cells, and the body regulates blood glucose even when dietary carbohydrate is severely restricted. Eliminating carbohydrates doesn't selectively starve a tumor, and clinical research has not established carbohydrate restriction as a universal cancer treatment. The more useful question is how different tumors regulate energy metabolism and whether those pathways can be targeted safely and effectively.
Ray Peat's Interpretation of Cancer Metabolism
Ray Peat placed considerable emphasis on the relationship between cellular energy production, thyroid function, stress hormones, and inflammation. He argued that impaired oxidative metabolism could create conditions that favor abnormal growth, particularly when cells become more dependent on glycolysis and lactate production. He also discussed the roles of carbon dioxide, progesterone, prostaglandins, and other signaling molecules in maintaining normal tissue function.
One of Peat's central ideas was that adequate energy production helps cells maintain their normal structure and function. When energy metabolism is impaired, stress signaling and inflammatory pathways can become more prominent, potentially changing how tissues respond to injury or disease. This perspective overlaps with established research showing that mitochondrial metabolism, inflammation, and cellular signaling are closely connected, although Peat's broader theory that metabolic impairment is the fundamental cause of cancer has not been established clinically.
Georgi Dinkov has expanded on these ideas in interviews and discussions of cancer metabolism, often focusing on compounds such as niacinamide, thiamine, aspirin, caffeine, and progesterone. Many of these substances influence biochemical pathways involved in energy production or inflammation, and some have been investigated in laboratory cancer models. Their effects are interesting, but they are not interchangeable, and evidence that a compound changes tumor-cell metabolism in a laboratory does not establish that it improves survival or causes tumor regression in humans.
I think the most valuable part of this framework is its emphasis on the metabolic environment. Cancer research increasingly recognizes that tumors interact with surrounding tissues, immune cells, circulating nutrients, and inflammatory signals. Understanding those relationships may lead to better treatments, but any proposed intervention still needs to be tested for its effects on actual patients, not just isolated cancer cells.
Niacinamide, NAD+, and Cellular Energy
Niacinamide, also called nicotinamide, is a form of vitamin B3 involved in the production of NAD+, a molecule essential for numerous metabolic reactions. NAD+ helps transfer electrons during energy production and participates in DNA repair and cellular signaling. Because cancer cells often have altered NAD+ metabolism, researchers have investigated whether changing these pathways might influence tumor growth or treatment response.
Some experimental studies suggest that nicotinamide can affect inflammatory signaling, DNA repair, and the behavior of certain cancer cells. However, the relationship between NAD+ and cancer is complicated because healthy cells and cancer cells both require it. Increasing NAD+ availability isn't automatically beneficial in every cancer setting, and some tumors rely on NAD+-producing pathways to support their growth.
There is meaningful human research on nicotinamide in cancer prevention, particularly in people at high risk of certain nonmelanoma skin cancers. A randomized clinical trial found that oral nicotinamide reduced the rate of new nonmelanoma skin cancers during treatment in a specific high-risk population. That finding is important, but preventing certain skin cancers is very different from treating an established internal malignancy. It doesn't establish that high-dose niacinamide shrinks tumors or improves survival in people with cancer.
For me, niacinamide illustrates why metabolic research is worth following while also showing why context matters. Supporting normal vitamin B3 status is an established nutritional goal, but high-dose supplementation during cancer treatment should be evaluated with the oncology team because the relevant pathways may have different effects depending on the tumor and treatment.
Thiamine and the Connection Between Glycolysis and Respiration
Thiamine, or vitamin B1, is another nutrient with an important role in energy metabolism. Its active form, thiamine pyrophosphate, is required by several enzymes, including pyruvate dehydrogenase, which helps convert pyruvate into acetyl-CoA for entry into the citric acid cycle. Adequate thiamine is therefore necessary for normal carbohydrate oxidation and mitochondrial energy production.
When thiamine is deficient, pyruvate metabolism can become impaired and lactate may accumulate. Correcting a deficiency can restore normal enzyme activity and improve the body's ability to use carbohydrate-derived energy. This relationship is especially relevant in people who are malnourished, have poor dietary intake, or develop deficiencies during serious illness.
Researchers have also investigated high-dose thiamine in laboratory models of cancer. Some experiments have reported changes in glycolysis, proliferation, and apoptosis, suggesting that thiamine-dependent pathways may influence cancer-cell behavior. However, these findings remain preliminary, and the effects of thiamine can vary across experimental conditions and tumor types. We don't have reliable clinical evidence that high-dose thiamine treats cancer or consistently reverses the Warburg effect in patients.
Thiamine also provides a useful connection to another area of cancer metabolism research: pyruvate dehydrogenase kinase. This enzyme can inhibit pyruvate dehydrogenase, influencing whether pyruvate enters mitochondrial oxidation or is directed toward other pathways. Experimental drugs such as dichloroacetate have been studied because they can alter this regulation, but their clinical effectiveness and safety remain uncertain. The research is scientifically interesting without establishing that nutritional thiamine supplementation produces the same effects as a targeted drug.
Aspirin, Prostaglandins, and Cancer Research
Aspirin has one of the more substantial histories of human research among the compounds frequently discussed in pro-metabolic cancer circles. It inhibits cyclooxygenase enzymes involved in prostaglandin production and affects platelet function, both of which are relevant to inflammation and certain aspects of tumor biology. Researchers have investigated whether these actions influence cancer development, progression, and the interaction between tumors and their surrounding environment.
Observational studies and some randomized trial analyses have associated aspirin use with a reduced incidence of colorectal cancer over long periods. However, the benefits depend on factors such as age, underlying risk, duration of use, and the outcomes being measured. More recent research has also highlighted important limitations, including a randomized trial in older adults that did not demonstrate an overall cancer benefit and raised concerns about cancer-related mortality.
Aspirin is also being studied in selected patients with established cancers, including investigations into whether particular molecular characteristics predict benefit. These questions are important because cancer is not one disease, and a treatment that helps one subgroup may offer no benefit or cause harm in another. Aspirin can produce serious gastrointestinal bleeding, ulcers, and other complications, and those risks may be especially significant during cancer treatment.
I understand why Peat and Dinkov were interested in aspirin's effects on prostaglandins and inflammatory signaling. Those mechanisms overlap with legitimate areas of cancer research, but they don't justify treating aspirin as a general-purpose anticancer supplement. Anyone considering aspirin during cancer care needs individualized medical guidance, particularly if surgery, chemotherapy, anticoagulants, or low platelet counts are involved.
Carbon Dioxide, Lactate, and Thyroid Function
Carbon dioxide is often treated as nothing more than a waste product of metabolism, but it also plays important physiological roles. It contributes to acid-base regulation, influences blood flow, and helps regulate oxygen delivery through its effects on hemoglobin. Ray Peat frequently discussed carbon dioxide as part of efficient oxidative metabolism, contrasting it with the increased lactate production seen in many stressed or rapidly growing tissues.
There is a biochemical basis for studying these relationships, but carbon dioxide and lactate levels are not simple measurements of whether a person has healthy or unhealthy mitochondria. Lactate is produced during normal physiology, including exercise, and it can serve as a useful fuel for other tissues. Likewise, increasing carbon dioxide is not an established cancer treatment, and blood or breath measurements cannot reliably tell us whether a tumor has shifted toward healthier metabolism.
Thyroid hormones also influence mitochondrial activity, energy expenditure, and the use of carbohydrates and fats. Adequate thyroid function is important for general health, and untreated hypothyroidism deserves appropriate evaluation and treatment. However, thyroid hormones can affect cancer biology in different ways, including potentially stimulating growth in some tumor types. Raising thyroid hormone levels above normal or using T3 specifically to influence tumor metabolism is not an established or reliably safe cancer treatment.
I think the practical lesson is to avoid overlooking ordinary physiological problems in someone dealing with a serious illness. Poor nutritional intake, thyroid dysfunction, anemia, sleep disruption, and nutrient deficiencies can all affect quality of life and treatment tolerance. Addressing these problems may be valuable, but it should not be confused with directly treating the cancer itself.
Nutrition and Metabolic Support During Cancer Care
One of the most important nutritional concerns during cancer treatment is inadequate energy intake. Many patients experience appetite loss, nausea, changes in taste, digestive problems, or unintentional weight loss, and some develop cancer-related cachexia involving substantial loss of muscle and physical function. In these circumstances, providing enough calories and protein can be more important than pursuing a restrictive dietary theory.
I generally favor carbohydrate-rich foods as useful sources of energy, particularly when they are easy to digest and help someone maintain adequate intake. Fruit, juice, potatoes, dairy foods, and other tolerated carbohydrate sources can contribute calories without requiring large amounts of dietary fat. However, cancer nutrition must be individualized, and some patients benefit from more energy-dense foods, including fats, when appetite is limited. A very-low-fat diet is not an established cancer treatment and may be counterproductive if it makes it harder to maintain weight or nutritional status.
Protein needs can also change during cancer treatment, especially when inflammation, surgery, or muscle loss increases the demand for tissue repair. This is one situation where my usual approach to moderate protein intake may need to be adjusted substantially. The goal is to preserve strength and nutritional status rather than impose a fixed macronutrient ratio on someone whose needs are changing.
I also believe it's important to distinguish normal nutritional support from high-dose supplement protocols. Correcting a documented deficiency is different from taking large doses of vitamins or medications in an attempt to alter tumor metabolism. Some supplements can interact with chemotherapy, radiation, anticoagulants, or other treatments, and compounds that appear protective in one experimental setting may have different effects in another. These decisions require coordination with the patient's oncology team.
Promising Findings in Metabolic Cancer Research
One of the most exciting developments in cancer research is the growing recognition that tumor metabolism may offer important therapeutic opportunities. For decades, much of cancer research focused on genetic mutations and the uncontrolled division of cells. Now, researchers are paying closer attention to how cancer cells produce energy, how they respond to metabolic stress, and whether changing their fuel supply or mitochondrial activity can influence their behavior.
The research on thiamine is particularly interesting because of its relationship to pyruvate dehydrogenase, the enzyme complex that helps direct glucose-derived fuel into mitochondrial respiration. In experimental cancer models, researchers have found that high-dose thiamine can reduce proliferation and alter glycolytic activity. Similar metabolic pathways have been investigated using dichloroacetate, which can promote pyruvate oxidation by inhibiting pyruvate dehydrogenase kinase. These findings suggest that the metabolic pathways controlling the balance between glycolysis and respiration may provide valuable targets for future therapies.
Niacinamide offers another fascinating direction. Its involvement in NAD+ metabolism connects it to cellular energy production, DNA repair, and the regulation of stress responses. Experimental research has identified several ways that nicotinamide metabolism influences cancer-cell behavior, while human research has demonstrated a preventive benefit against certain nonmelanoma skin cancers in high-risk individuals. I find this especially encouraging because it shows how a familiar nutrient can influence biological pathways with meaningful implications for cancer research.
Aspirin may be even more intriguing because of the extensive human research surrounding its effects on prostaglandins, inflammation, and cancer risk. Studies have identified associations between long-term aspirin use and reduced colorectal cancer incidence in certain populations, while ongoing research continues to explore its potential role in selected cancers. The involvement of inflammatory prostaglandins, platelets, and tumor signaling provides several possible mechanisms through which this inexpensive, familiar compound may influence cancer biology.
What ties these findings together is the possibility that cancer cells have metabolic vulnerabilities that can be influenced through relatively simple biochemical pathways. That is an exciting direction for research, particularly because many of the compounds being investigated are already familiar to scientists and clinicians. Understanding how they affect specific cancers, and how they might complement existing treatments, could open important new possibilities.
Why Carbohydrates Matter in the Cancer Metabolism Conversation
One of the most unfortunate interpretations of the Warburg effect is the idea that because cancer cells consume glucose, people with cancer should avoid carbohydrates. This overlooks the fact that glucose is also an essential fuel for healthy tissues, including the brain, immune system, and red blood cells. Normal cells use glucose through glycolysis and, when oxygen and mitochondrial function permit, oxidize its products to produce substantial amounts of ATP. The presence of glucose isn't the problem Warburg was describing; he was interested in why cancer cells metabolize it differently.
Carbohydrate restriction also doesn't eliminate glucose from the bloodstream. The liver continues producing glucose through gluconeogenesis and glycogen breakdown because maintaining blood glucose is essential for survival. When dietary carbohydrates are limited, the body must rely more heavily on alternative fuels and internally produced glucose. Depending on energy intake and physiological circumstances, this can involve changes in thyroid hormone metabolism and increased reliance on stress-related pathways, which may be especially relevant for someone already dealing with poor appetite, weight loss, or inadequate nourishment.
Ray Peat emphasized that carbohydrate availability helps support oxidative metabolism, particularly when thyroid function and mitochondrial enzyme systems are working properly. Glucose oxidation produces carbon dioxide, while the balance between glucose oxidation and lactate production depends on cellular conditions, oxygen availability, and enzyme regulation. This is one reason I find the metabolic approach so interesting: rather than treating glucose itself as the enemy, it encourages us to examine what determines whether cells use glucose efficiently.
From a nutritional perspective, adequate carbohydrates can help people maintain energy intake, replenish glycogen, and preserve protein for tissue maintenance rather than using it as a source of glucose. Fruit, juice, potatoes, honey, milk, and other easily tolerated carbohydrate sources can be useful when someone is struggling to eat enough. For patients undergoing cancer treatment, the appropriate balance of carbohydrate, protein, and fat should reflect their nutritional status, digestive tolerance, and treatment needs.
I believe the larger conversation should focus on supporting healthy glucose metabolism rather than creating unnecessary fear around carbohydrates. Cancer metabolism is far more complex than the idea that eating sugar directly causes tumor growth, and the research into mitochondrial function offers a much more interesting way to understand what is happening inside cells. The goal is to nourish healthy tissues while researchers continue investigating the metabolic vulnerabilities of cancer cells.
The Bigger Picture: Restoring Healthy Cellular Metabolism
Ray Peat's work emphasized the importance of efficient oxidative metabolism, adequate energy availability, and the relationship between mitochondrial function and cellular health. Georgi Dinkov has continued exploring these ideas, drawing attention to research on vitamins, salicylates, hormones, and other compounds that influence metabolic signaling. Their perspective encourages us to consider the biochemical environment in which disease develops, including the roles of inflammation, stress hormones, energy production, and the availability of essential nutrients.
I find this framework valuable because it connects so many areas of physiology that are often discussed separately. Thyroid function influences energy expenditure, B vitamins participate in mitochondrial enzyme systems, prostaglandins affect inflammation and cellular signaling, and carbohydrate metabolism provides essential fuel for normal tissues. These processes interact continuously, and understanding those relationships may help researchers identify new ways to influence abnormal cellular behavior.
For people facing cancer, supporting nutritional status, correcting deficiencies, maintaining strength, and addressing metabolic problems are important parts of comprehensive care. Adequate nourishment also creates a better foundation for recovery and treatment tolerance. I believe metabolic health deserves more attention in this conversation, both for its role in normal physiology and for the emerging research into the metabolic characteristics of tumors.
Final Thoughts
Nearly a century after Otto Warburg first described the unusual glucose metabolism of cancer cells, his observations remain central to an expanding field of research. Scientists are discovering increasingly complex relationships between mitochondrial respiration, lactate production, inflammation, cellular signaling, and tumor growth. What began as an observation about how cancer cells use glucose has developed into an entire area of research exploring whether their metabolic adaptations can become therapeutic targets.
This is why I find the work of Ray Peat and Georgi Dinkov so compelling. Their emphasis on energy metabolism encourages us to ask questions about cancer that extend beyond the traditional focus on genetic mutations and cell division. The findings involving thiamine, niacinamide, aspirin, and mitochondrial pathways offer promising directions for continued investigation, and some have already produced meaningful results in human research.
I believe this is one of the most fascinating areas of modern cancer research. The more we learn about how cells produce energy, respond to stress, and regulate growth, the more opportunities we may discover to influence those processes. Warburg opened an important door nearly a century ago, and we're still learning just how much lies on the other side.
References
Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314. PMID: 13298683.
Liberti MV, Locasale JW. The Warburg effect: How does it benefit cancer cells? Trends in Biochemical Sciences. 2016;41(3):211–218. PMID: 26778478.
DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Science Advances. 2016;2(5). PMID: 27386546.
Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metabolism. 2016;23(1):27–47. PMID: 26771115.
Chen AC, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. New England Journal of Medicine. 2015;373:1618–1626. PMID: 26488693.
Hanberry BS, Berger R, Zastre JA. High-dose vitamin B1 reduces proliferation in cancer cell lines analogous to dichloroacetate. Cancer Chemotherapy and Pharmacology. 2014;73:585–594.
Bonnet S, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007;11(1):37–51. PMID: 17222789.
Rothwell PM, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. The Lancet. 2010;376(9754):1741–1750. PMID: 20970847.
McNeil JJ, et al. Effect of aspirin on cancer incidence and mortality in older adults. Journal of the National Cancer Institute. 2021;113(3):258–265. PMID: 32623001.
Peat R. Selected essays on cancer, oxidative metabolism, and cellular energy. Available through the Ray Peat essay archive.
